 WARMER, Pa., July 29, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021. The schedule for the press release and conference callwebcast are as follows: 